The effect of insulin deprivation on fasting levels of 5000 dalton gastric inhibitory polypeptide in type 1 (insulin-dependent) diabetics. 1985

T Krarup, and S Madsbad, and L Regeur, and K G Alberti, and O K Faber, and A Kurtz

To investigate whether metabolic decompensation has an effect on gastric inhibitory polypeptide (GIP), 8 fasting male type 1 diabetics were deprived of insulin for 12 h. An overnight insulin infusion aiming at normoglycaemia was stopped at 08.00 h. During the following 12 h blood glucose increased from 7.0 +/- 0.4 to 14.9 +/- 1.0 mmol/l, P less than 0.01, 3-hydroxy-butyrate from 0.18 +/- 0.07 to 4.00 +/- 0.74 nmol/1, P less than 0.01, and immunoreactive GIP (IR-GIP) from 16.7 +/- 2.6 to 21.9 +/- 2.9 pmol/1, P less than 0.05. The antiserum employed, R65, only measures 5000 dalton IR-GIP. The final IR-GIP concentrations were not significantly different from fasting IR-GIP concentrations in 13 normal male subjects (17.4 +/- 1.5 pmol/1). Short term insulin deprivation therefore is associated with a slight increase in fasting IR-GIP concentrations. Whether this modest increase in IR-GIP significantly enhances insulin secretion is unknown.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D005215 Fasting Abstaining from FOOD. Hunger Strike,Hunger Strikes,Strike, Hunger,Strikes, Hunger
D005749 Gastric Inhibitory Polypeptide A gastrointestinal peptide hormone of about 43-amino acids. It is found to be a potent stimulator of INSULIN secretion and a relatively poor inhibitor of GASTRIC ACID secretion. Glucose-Dependent Insulinotropic Peptide,Gastric-Inhibitory Polypeptide,Glucose Dependent Insulinotropic Peptide,Glucose-Dependent Insulin-Releasing Peptide,Glucose Dependent Insulin Releasing Peptide,Inhibitory Polypeptide, Gastric,Insulin-Releasing Peptide, Glucose-Dependent,Insulinotropic Peptide, Glucose-Dependent,Peptide, Glucose-Dependent Insulin-Releasing,Peptide, Glucose-Dependent Insulinotropic,Polypeptide, Gastric Inhibitory,Polypeptide, Gastric-Inhibitory
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006885 Hydroxybutyrates Salts and esters of hydroxybutyric acid. Hydroxybutyric Acid Derivatives,Hydroxybutyric Acids,Acid Derivatives, Hydroxybutyric
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D020155 3-Hydroxybutyric Acid BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver. 3-Hydroxybutyrate,beta-Hydroxybutyrate,(+ -)-3-Hydroxybutyric Acid,beta-Hydroxybutyric Acid,3 Hydroxybutyrate,3 Hydroxybutyric Acid,beta Hydroxybutyrate,beta Hydroxybutyric Acid

Related Publications

T Krarup, and S Madsbad, and L Regeur, and K G Alberti, and O K Faber, and A Kurtz
February 1981, Clinical endocrinology,
T Krarup, and S Madsbad, and L Regeur, and K G Alberti, and O K Faber, and A Kurtz
August 1979, The Journal of clinical endocrinology and metabolism,
T Krarup, and S Madsbad, and L Regeur, and K G Alberti, and O K Faber, and A Kurtz
November 1982, Irish journal of medical science,
T Krarup, and S Madsbad, and L Regeur, and K G Alberti, and O K Faber, and A Kurtz
January 1982, Acta medica Scandinavica,
T Krarup, and S Madsbad, and L Regeur, and K G Alberti, and O K Faber, and A Kurtz
April 1980, Pediatric research,
T Krarup, and S Madsbad, and L Regeur, and K G Alberti, and O K Faber, and A Kurtz
January 1980, Diabetes,
T Krarup, and S Madsbad, and L Regeur, and K G Alberti, and O K Faber, and A Kurtz
January 1982, Digestion,
T Krarup, and S Madsbad, and L Regeur, and K G Alberti, and O K Faber, and A Kurtz
January 2018, Current diabetes reviews,
T Krarup, and S Madsbad, and L Regeur, and K G Alberti, and O K Faber, and A Kurtz
January 1986, Scandinavian journal of gastroenterology,
T Krarup, and S Madsbad, and L Regeur, and K G Alberti, and O K Faber, and A Kurtz
November 1975, The Journal of clinical investigation,
Copied contents to your clipboard!